| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Endogenous metabolite; uridine-cytidine kinase; CTP synthetase; RNA polymerase; pyrimidine nucleoside transporters. Cytidine is phosphorylated by uridine-cytidine kinase to CMP, which is converted to CDP and CTP for RNA synthesis. It also serves as a precursor for uridine and modulates neurotransmitter cycling and mitochondrial function.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a labeled metabolite, Cytidine-13C exhibits the same intrinsic biological activity as unlabeled cytidine. It is incorporated into RNA and serves as a substrate for uridine-cytidine kinase. In vitro, it supports nucleotide salvage pathway studies and RNA synthesis measurements. It also modulates glial glutamate cycling and affects cerebral phospholipid metabolism. |
| ln Vivo |
In vivo, Cytidine-13C is used for metabolic tracing of RNA synthesis and nucleoside metabolism. Following administration, the 13C label is incorporated into tissue RNA, enabling quantification of RNA turnover in liver, brain, and other organs. It also supports studies of cytidine transport and pyrimidine metabolism in vivo.
|
| Enzyme Assay |
For enzyme assays, incubate uridine-cytidine kinase with Cytidine-13C (0.1-10 mM) and ATP in assay buffer at 37°C. Measure CMP formation by HPLC or LC-MS/MS. For RNA synthesis assays, pulse cells with Cytidine-13C (100-500 μM) for 15-60 minutes. Extract RNA, digest to nucleosides, and quantify 13C enrichment by LC-MS/MS.
|
| Cell Assay |
For metabolic labeling, culture cells with Cytidine-13C (10-100 μM) for 24-72 hours. Extract RNA and digest to nucleosides. Quantify 13C enrichment in cytidine by LC-MS/MS. For RNA turnover studies, pulse cells with Cytidine-13C and chase with excess unlabeled cytidine. Determine RNA half-life.
|
| Animal Protocol |
For in vivo metabolic tracing, mice receive Cytidine-13C (10-50 mg/kg) via intraperitoneal injection or oral gavage. Collect liver and brain at 0-24 hours. Extract RNA, digest to nucleosides, and analyze by LC-MS/MS to quantify 13C enrichment. For neurotransmitter studies, measure brain tissue levels of catecholamines by HPLC.
|
| References |
| Molecular Formula |
C9H13N3O5
|
|---|---|
| Molecular Weight |
244.209276914597
|
| Exact Mass |
244.088
|
| CAS # |
201996-57-8
|
| Related CAS # |
Cytidine;65-46-3
|
| PubChem CID |
121596077
|
| Appearance |
White to off-white solid
|
| LogP |
-2.1
|
| tPSA |
129
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
383
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)N=C1N)[13C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
|
| InChi Key |
UHDGCWIWMRVCDJ-URLSOCJKSA-N
|
| InChi Code |
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8-/m1/s1/i8+1
|
| Chemical Name |
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)(213C)oxolan-2-yl]pyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0948 mL | 20.4742 mL | 40.9484 mL | |
| 5 mM | 0.8190 mL | 4.0948 mL | 8.1897 mL | |
| 10 mM | 0.4095 mL | 2.0474 mL | 4.0948 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.